PLAINSBORO, N.J., Feb. 16, 2011 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today the launch of Trel-XPress™ Demineralized Bone Matrix, expanding its portfolio of bone graftingsubstitutes for the orthopedic extremity reconstruction surgeon, which includes Integra OS® Osteoconductive Scaffold, a synthetic bone void filler manufactured from beta tri-calcium phosphate and type I bovine collagen; Trel-X(TM), a demineralized bone matrix; and Trel-XC®, a demineralized bone matrix premixed with cancellous bone.
Trel-XPress™ Demineralized Bone Matrix is powered by Accell® technology and is composed of an optimized blend of particulate Demineralized Bone Matrix (DBM), Integra’s proprietary Accell® Bone Matrix (ABM), and a reverse phase medium poloxamer. ABM is an open structured and more dispersed form of DBM, providing a high surface area environment that encourages bone formation.
“Integra offers one of the most comprehensive orthobiologics portfolios for the extremity reconstructive surgeon, and the introduction of Trel-XPress™ Demineralized Bone Matrix reinforces our commitment to give surgeons more solutions for their patients,” said Robert Paltridge, President of Integra Extremity Reconstruction.
Surgeons frequently remove bone from the spine, extremities and pelvis that has been damaged by trauma, degenerative conditions and aging. Bone grafts are generally needed to fill in these defects and aid the body in regenerating new bone. Bone grafts provide a foundation or scaffold for the patient’s body to grow new bone, and encourage new bone production and bone fusion.
Surgeons have historically obtained healthy bone graft material from the patient’s own body, often from the iliac crest of the pelvis. Sourcing bone graft material in this manner requires additional surgery that may cause post-operative pain, and there is also a limit on how much of the patient’s bone may be removed from the donor site.
Trel-XPress™ Demineralized Bone Matrix offers an alternative for use as a bone graft in orthopedic extremity reconstruction surgeries. It may reduce the need to harvest the patient’s own bone, sparing the patient additional surgery and limiting the risk of any associated complications.
The U.S. market size for bone graft substitutes in orthopedic extremity reconstruction procedures was approximately $80 million in 2010.
Trel-XPress™ Demineralized Bone Matrix will be sold by Integra’s Extremity Reconstruction sales organization, which focuses on lower extremity fixation, upper extremity fixation, tendon protection, peripheral nerve repair/protection and wound repair.
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of Integra products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, economic, competitive, governmental, technological and other factors identified under the heading “Risk Factors” included in Item IA of Integra’s Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Gianna Sabella